Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Marker Therapeutics, Inc. | v464986_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - Marker Therapeutics, Inc. | v464986_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Marker Therapeutics, Inc. | v464986_ex31-1.htm |
| 10-Q - FORM 10-Q - Marker Therapeutics, Inc. | v464986_10q.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned, Glynn Wilson, the Chief Executive Officer of TapImmune Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune Inc., for the quarterly period ended March 31, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of TapImmune Inc.
| Date: | May 5, 2017 |
| /s/ Glynn Wilson | ||
| Glynn Wilson | ||
| Chief Executive Officer |